What Is Pyxis Oncology, Inc. (PYXS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pyxis Oncology, Inc.'s intrinsic value is estimated at a composite fair value of $1.63. Trading at $2.43, the stock is approaching fair value or slight overvaluation (implied return of -33.1%), as 8 of 11 models suggest limited further upside. Notably, EROIC sees the most upside at +134.5% (fair value: $5.70), while ML-RIV is the most conservative at -96.5% ($0.08). The spread between these extremes — +231.0% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About PYXS?
11 of 13 models are currently active for PYXS. Of these, 3 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates PYXS's intrinsic value at $0.50, implying -79.4% downside from the current price. See which stocks rank higher →
How Does PYXS Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, PYXS ranks #178 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Pyxis Oncology, Inc.'s positioning within the Pharmaceutical Preparations segment means that patent cliff exposure plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.
Is PYXS a Value Trap?
CirclFi's Value Trap algorithm assigns PYXS a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Pyxis Oncology, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Pyxis Oncology, Inc. earns a quality score of 5.2/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +231.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PYXS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PYXS's 11 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad